The problem of tobacco smoking
Health benefits of smoking cessation
Stopping smoking has substantial immediate and long term health benefits for smokers of all ages. The excess risk of death from smoking falls soon after cessation and continues to do so for at least 10-15 years. Former smokers live longer than continuing smokers, no matter what age they stop smoking, though the impact of quitting on mortality is greatest at younger ages. For smokers who stop before age 35, survival is about the same as that for non-smokers.
The rate and extent of reduction of risk varies between diseases —for lung cancer the risk falls over 10 years to about 30% - 50% that of continuing smokers, but the risk remains raised even after 20 years of abstinence. There is benefit from quitting at all ages, but stopping before age 30 removes 90% of the lifelong risk of lung cancer. The excess risk of oral and oesophageal cancer caused by smoking is halved within five years of cessation.
Key points
- Cigarette smoking is one of the greatest avoidable causes of premature death and disability in the world
- Helping smokers to stop smoking is one of the most cost effective interventions available in clinical practice
- Promoting smoking cessation should therefore be a major priority in all countries and for all health professionals in all clinical settings
Numbers and relative risk of death (by cause) due to smoking, United
Kingdom. Data from Tobacco Advisory Group of the Royal College of
Physicians and Doll et al
The risk of heart disease decreases much more quickly after quitting smoking. Within a year the excess mortality due to smoking is halved, and within 15 years the absolute risk is almost the same as in people who have never smoked. In a meta-analysis by Wilson and colleagues in 2000, the odds ratio for death for smokers who stopped smoking after myocardial infarction was 0.54, a far higher protective effect than the 0.75-0.88 odds ratio for death achieved by the conventional standard treatments for myocardial infarction, including thrombolysis, aspirin, β blockers, and statins. Smoking cessation also reduces the risk of death after a stroke and of death from pneumonia and influenza.
Smoking is associated with an accelerated rate of decline in lung function with age. Cessation results in a small increase in lung function and reverses the effect on subsequent rate of decline, which reverts to that in non-smokers.
Effect of smoking cessation on rate of decline in lung function in chronic
obstructive pulmonary disease. Adapted from Anthonisen et al. Am J Respir
Crit Care Med 2002;166:675-9
Thus, early cessation is especially important in susceptible individuals to prevent or delay the onset of chronic obstructive pulmonary disease. In patients with this disease, mortality and symptoms are reduced in former smokers compared with continuing smokers. Recent evidence shows that the benefits occur even in older patients with severe chronic obstructive pulmonary disease.
Stopping smoking before or in the first three to four months of pregnancy protects the fetus against the reduced birth weight associated with smoking.
Preoperative cessation reduces perioperative mortality and complications
At a population level, the importance of smoking cessation is paramount. Peto has estimated that current cigarette smoking will cause about 450 million deaths worldwide in the next 50 years. Reducing current smoking by 50% would prevent 20-30 million premature deaths in the first quarter of this century and about 150 million in the second quarter. Preventing young people from starting smoking would have a more delayed but ultimately even greater impact on mortality.
Effective prevention of cigarette smoking and help for those wishing to quit can therefore yield enormous health benefits for populations and individuals. Promoting and supporting smoking cessation should be an important health policy priority in all countries and for healthcare professionals in all clinical settings. However, this has not so far generally been reflected at a policy level or in the practice of individual healthcare professionals.
Competing interests: RE is chairman of North West ASH (Action on Smoking and Health); he receives no financial reward for this work. JB has been reimbursed by GlaxoWellcome (now GlaxoSmithKline) for attending two international conferences, has received a speaker’s honorarium from GlaxoWellcome, and has been the principal investigator in a clinical trial of nicotine replacement therapy funded by Pharmacia. Both these companies manufacture nicotine replacement products.
JOHN BRITTON
Professor of Epidemiology at the University of Nottingham
References
- Tobacco Advisory Group of the Royal College of Physicians.
- Nicotine addiction in Britain. London: Royal College of Physicians of London, 2000. http://www.rcplondon.ac.uk/pubs/books/nicotine/index.htm
- Jha P, Chaloupka F, eds. Tobacco control in developing countries. Oxford: Oxford University Press, 1999.
- Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ 1994;309:901-11.
- World Bank. Curbing the epidemic: governments and the economics of tobacco control. Washington, DC: World Bank, 1999. www1.worldbank.org/tobacco/reports.asp
- US Department of Health and Human Services. The health benefits of smoking cessation: a report of the surgeon general. Rockville, MD: US Government Printing Office, 1990. (DHHS publication No (CDC) 90-8416.)
- Wilson K, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction. Arch Intern Med 2000;160:939-44.